Similar companies
Income Statement (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Operating expense | 59M | 10.5% |
| Net Income | -56M | 12.9% |
Balance Sheet (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Total Assets | 345M | 13.1% |
| Total Liabilities | 88M | 5.7% |
| Total Equity | 257M | 15.4% |
| Shares Outstanding | 61M | 1.4% |
Cash Flow (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Cash from operations | -49M | 2.5% |
| Cash from financing | 500,000 | 388.2% |
EPS
Financial Highlights for Pliant Therapeutics in Q1 '25
Operating Expenses for this period were 59M, showing a 10.5% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -56M, showing a -12.9% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
Pliant Therapeutics faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies.
